Statement Of Investors' Complaints As On December 31, 2017
In compliance with the provisions of Regulation 13[3] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, the status of Investor Complaints as on December 31, 2017 is as per attached letter. Zydus Pharmaceuticals receives USFDA nod to market OCD treatment drug
Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd Zydus Healthcare moves India marketing operations to Mumbai
Zydus Healthcare is a wholly owned subsidiary of Cadila Healthcare Zydus Wellness CFO resigns
Zydus Wellness today said its Chief Financial Officer Amit B Jain has resigned from the company. Amit B Jain has tendered his resignation as the Chief Financial Officer (Key Managerial Personnel)... Resignation of Chief Financial Officer (CFO)
We inform that Mr. Amit B. Jain has tendered his resignation as the Chief Financial Officer (Key Managerial Personnel) of the Company. Zydus gets USFDA nod for schizophrenia treatment drug
Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clozapine tablets, used in the treatment of severe schizophrenia. The company has got final... Zydus gets tentative US FDA nod to sell pregabalin for seizures, pain
The drug will be produced at the group's formulations manufacturing facility in Moraiya, Ahmedabad Zydus gets USFDA nod for seizures, migraine drug; shares down 0.6%
Zydus Cadila has received final approval from the US health regulator to market topiramate extended release capsules used for the treatment of seizures and migraine. The company has received... Zydus' oral small molecule named Desidustat by WHO
Drug firm Zydus Cadila today said its oral anaemia developmental candidate, ZYAN1, has been named Desidustat by the World Health Organisation (WHO) INN Committee. The International Non-proprietary... Unaudited Financial Results For The Quarter / Half Year Ended On 30.09.2017
Unaudited Financial Results for the quarter / half year ended on 30.09.2017 along with limited review report [standalone and consolidated] and press release.